First-Line Nivolumab in Advanced Lung Cancer Fails to Improve Outcomes

Nivolumab did not extend progression-free survival over chemotherapy in the first-line setting in patients with PD-L1 –positive advanced non–small-cell lung cancer, according to results of an open-label phase III trial. (Source: CancerNetwork)

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2tEAMPa
via IFTTT